Compare McDonald's Corp (MCD) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
McDonald's Corp vs Novo Nordisk A/S — how do they compare? McDonald's Corp trades at $235.23 (market cap $167.64B), while Novo Nordisk A/S trades at $38.64 (market cap $165.31B). The key difference: McDonald's Corp and Novo Nordisk A/S are close in size by market cap, and Novo Nordisk A/S pays the higher dividend (4.71%). Which is the better fit depends on your goals — on Pluang, investors hold McDonald's Corp for 164 Days and Novo Nordisk A/S for 116 Days on average.
| MCD | NVO | |
|---|---|---|
Market Cap | $167.64B | $165.31B |
Volume | 11,320,306 | 11,432,838 |
Sector | Consumer Cyclical | Health |
52-Week High | $341.06 | $63.98 |
52-Week Low | $230.88 | $35.29 |
Typical Hold Time | 164 Days | 116 Days |
Enterprise Value | $221.41B | $179.56B |
Dividend Yield | 3.26% | 4.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
McDonald's (MCD) trades at $236.9, up 2.61% today, but technical indicators signal a bearish trend. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $3.38 exceeding the $3.32 estimate. Revenue growth remains steady, reaching $26.89B in 2025, while net income margin stands at 31.72%. Recent news highlights the launch of the 'McDonald's NEXT' strategy focusing on automation and improved customer experience to drive growth amid competitive pressures.
The outlook for MCD is mixed: analyst consensus is bullish with a $284.70 price target, but technical weakness and inflation risks pose challenges. Investment appeal lies in its robust profitability and dividend payments, though high debt levels and margin pressures from rising costs require monitoring for sustained shareholder value.
Novo Nordisk (NVO) trades at $38.18, down 0.21% with a bearish technical signal. The stock shows strong fundamentals with consistent earnings beats (Q4 2025-Q2 2026) and robust profitability (35.35% net margin, 59.82% ROE). Recent news highlights pipeline developments including Wegovy pill data and a $4 billion licensing deal, though the FDA extended review of its hemophilia drug. Cash flow remains positive at $10.81B for 2025, supporting dividend payments.
NVO presents a compelling value opportunity with a 9.66 P/E ratio and 17% upside to the $44.67 consensus target. However, competitive pressure from Eli Lilly's obesity drug pipeline and regulatory delays pose near-term risks. Analyst sentiment is bullish (59% buy ratings), but investors should monitor Q3 2026 earnings against the 0.753 EPS expectation for confirmation of growth trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About McDonald's Corp
McDonald's Corporation franchises and operates fast-food restaurants in the global restaurant industry. The Company's restaurants serves a variety of value-priced menu products in countries around the world.
Read more on MCD →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
